168 related articles for article (PubMed ID: 32780186)
1. A Case of Severe Acute Gastritis as an Immune-Related Adverse Event After Nivolumab Treatment: Endoscopic and Pathological Findings in Nivolumab-Related Gastritis.
Ebisutani N; Tozawa K; Matsuda I; Nakamura K; Tamura A; Hara K; Kondo T; Terada T; Tomita T; Oshima T; Fukui H; Hirota S; Miwa H
Dig Dis Sci; 2021 Jul; 66(7):2461-2465. PubMed ID: 32780186
[No Abstract] [Full Text] [Related]
2. Severe steroid refractory gastritis induced by Nivolumab: A case report.
Vindum HH; Agnholt JS; Nielsen AWM; Nielsen MB; Schmidt H
World J Gastroenterol; 2020 Apr; 26(16):1971-1978. PubMed ID: 32390707
[TBL] [Abstract][Full Text] [Related]
3. Multiplexed imaging reveals an IFN-γ-driven inflammatory state in nivolumab-associated gastritis.
Ferrian S; Liu CC; McCaffrey EF; Kumar R; Nowicki TS; Dawson DW; Baranski A; Glaspy JA; Ribas A; Bendall SC; Angelo M
Cell Rep Med; 2021 Oct; 2(10):100419. PubMed ID: 34755133
[TBL] [Abstract][Full Text] [Related]
4. Bilateral Vocal Cord Paralysis Due to an Immune-related Adverse Event of Nivolumab: A Case Report.
Willegers T; Honings J; Bekkers S
J Immunother; 2020 Sep; 43(7):230. PubMed ID: 32520826
[No Abstract] [Full Text] [Related]
5. [Myasthenia gravis associated with nivolumab].
Miñón-Fernández B; Losada-Domingo JM; Sánchez-Horvath MT; Bárcena-Llona J
Rev Neurol; 2020 Jan; 70(2):72-73. PubMed ID: 31930473
[TBL] [Abstract][Full Text] [Related]
6. Acute Ulceronecrotic Gastritis With Cytomegalovirus Reactivation: Uncommon Toxicity of Immune Checkpoint Inhibitors in Microsatellite Instability-High Metastatic Colorectal Cancer.
Hulo P; Touchefeu Y; Cauchin E; Archambeaud I; Chapelle N; Bossard C; Bennouna J
Clin Colorectal Cancer; 2020 Dec; 19(4):e183-e188. PubMed ID: 32703755
[No Abstract] [Full Text] [Related]
7. Bilateral Vocal Cord Paralysis Due to an Immune-related Adverse Event of Nivolumab: A Case Report.
Willegers T; Janssen JBE; Boers-Sonderen MJ; Bekkers S
J Immunother; 2020 Apr; 43(3):93-94. PubMed ID: 32011418
[TBL] [Abstract][Full Text] [Related]
8. Development of Severe Heart Failure in a Patient with Squamous Non-small-cell Lung Cancer During Nivolumab Treatment.
Samejima Y; Iuchi A; Kanai T; Noda Y; Nasu S; Tanaka A; Morishita N; Suzuki H; Okamoto N; Harada H; Ezumi A; Ueda K; Kawahara K; Hirashima T
Intern Med; 2020 Aug; 59(16):2003-2008. PubMed ID: 32448839
[TBL] [Abstract][Full Text] [Related]
9. [New AMM: Nivolumab for advanced oesophageal squamous cell carcinomia after first line of chemotherapy].
Reich M; Coutzac C
Bull Cancer; 2021 Mar; 108(3):228-229. PubMed ID: 33531154
[No Abstract] [Full Text] [Related]
10. Clinical, Endoscopic, and Pathological Characteristics of Immune Checkpoint Inhibitor-Induced Gastroenterocolitis.
Hayashi Y; Hosoe N; Takabayashi K; Limpias Kamiya KJL; Tsugaru K; Shimozaki K; Hirata K; Fukuhara K; Fukuhara S; Mutaguchi M; Sujino T; Sukawa Y; Hamamoto Y; Naganuma M; Takaishi H; Shimoda M; Ogata H; Kanai T
Dig Dis Sci; 2021 Jun; 66(6):2129-2134. PubMed ID: 32621258
[No Abstract] [Full Text] [Related]
11. A case of Schönlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma.
Belkaid S; Berger M; Nouvier M; Picard C; Dalle S
Eur J Cancer; 2020 Nov; 139():169-172. PubMed ID: 32992155
[No Abstract] [Full Text] [Related]
12. Palmoplantar Pustulosis Caused by Immune-Checkpoint Inhibitors.
Furuta H; Kato S; Masago K; Hida T
Clin Lung Cancer; 2021 Nov; 22(6):e829-e832. PubMed ID: 34023207
[No Abstract] [Full Text] [Related]
13. Dual checkpoint inhibitor-associated eosinophilic enteritis.
Yang J; Lagana SM; Saenger YM; Carvajal RD
J Immunother Cancer; 2019 Nov; 7(1):310. PubMed ID: 31730503
[TBL] [Abstract][Full Text] [Related]
14. Checkpoint Inhibitor-Induced Hemorrhagic Gastritis with Pembrolizumab.
Rao BB; Robertson S; Philpott J
Am J Gastroenterol; 2019 Feb; 114(2):196. PubMed ID: 30353060
[No Abstract] [Full Text] [Related]
15. Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature.
Messer A; Drozd B; Glitza IC; Lu H; Patel AB
Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941716
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitor-Induced Ptosis in a Patient With Prostate Cancer.
Williams KJ; Allen RC
J Neuroophthalmol; 2021 Mar; 41(1):e71-e72. PubMed ID: 32235233
[No Abstract] [Full Text] [Related]
17. Clinical characteristics, diagnosis, treatment, and prognosis of nivolumab induced gastritis.
Lei H; Sun W; Liu X; Wang C
Invest New Drugs; 2024 Feb; 42(1):53-59. PubMed ID: 38063991
[TBL] [Abstract][Full Text] [Related]
18. Fisher syndrome as an immune-related adverse event after using pembrolizumab but not nivolumab.
Nakamagoe K; Yamada T; Okune S; Moriwaki T; Tamaoka A
Acta Neurol Belg; 2021 Oct; 121(5):1381-1382. PubMed ID: 33641036
[No Abstract] [Full Text] [Related]
19. Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up.
McClure T; Cui W; Asadi K; John T; Testro A
BMJ Open Gastroenterol; 2020 Sep; 7(1):. PubMed ID: 32912846
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab-associated active neutrophilic gastritis.
Rovedatti L; Lenti MV; Vanoli A; Feltri M; De Grazia F; Di Sabatino A
J Clin Pathol; 2020 Sep; 73(9):605-606. PubMed ID: 32161070
[No Abstract] [Full Text] [Related]
[Next] [New Search]
